TEST PERFORMED AT KOS DIAGNOSTIC LAB, AMBALA CANTT.

NAME	: Mrs. GURPREET KAUR		
AGE/ GENDER	: 40 YRS/FEMALE	**PATIENT ID**	: 1563802
COLLECTED BY	:	**REG. NO./LAB NO.**	: 122407290013
REFERRED BY	:	**REGISTRATION DATE**	: 29/Jul/2024 11:08 AM
BARCODE NO.	: 12503875	**COLLECTION DATE**	: 29/Jul/2024 11:45AM
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INSTITUTE	**REPORTING DATE**	: 29/Jul/2024 04:37PM
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA		

Test Name	Value	Unit	Biological Reference interval

HAEMATOLOGY
GLYCOSYLATED HAEMOGLOBIN (HBA1C)

Test Name	Value	Unit	Biological Reference interval
GLYCOSYLATED HAEMOGLOBIN (HbA1c): **WHOLE BLOOD** *by HPLC (HIGH PERFORMANCE LIQUID CHROMATOGRAPHY)*	9.5^H	%	4.0 - 6.4
ESTIMATED AVERAGE PLASMA GLUCOSE *by HPLC (HIGH PERFORMANCE LIQUID CHROMATOGRAPHY)*	225.95^H	mg/dL	60.00 - 140.00

INTERPRETATION:

AS PER AMERICAN DIABETES ASSOCIATION (ADA):		
REFERENCE GROUP	**GLYCOSYLATED HEMOGLOGIB (HBAIC) in %**	
Non diabetic Adults >= 18 years	<5.7	
At Risk (Prediabetes)	5.7 – 6.4	
Diagnosing Diabetes	>= 6.5	
	Age > 19 Years	
Therapeutic goals for glycemic control	Goals of Therapy:	< 7.0
	Actions Suggested:	>8.0
	Age < 19 Years	
	Goal of therapy:	<7.5

COMMENTS:

1.Glycosylated hemoglobin (HbA1c) test is three monthly monitoring done to assess compliace with therapeutic regimen in diabetic patients.

2.Since Hb1c reflects long term fluctuations in blood glucose concentration, a diabetic patient who has recently under good control may still have high concentration of HbAlc. Converse is true for a diabetic previously under good control but now poorly controlled.

3.Target goals of < 7.0 % may be beneficial in patients with short duration of diabetes, long life expectancy and no significant cardiovascular disease. In patients with significant complications of diabetes, limited life expectancy or extensive co-morbid conditions, targetting a goal of < 7.0% may not be appropiate.
4.High
HbA1c (>9.0 -9.5 %) is strongly associated with risk of development and rapid progression of microvascular and nerve complications

5.Any condition that shorten RBC life span like acute blood loss, hemolytic anemia falsely lower HbA1c results.

6.HbA1c results from patients with HbSS,HbSC and HbD must be interpreted with caution , given the pathological processes including anemia,increased red cell turnover, and transfusion requirement that adversely impact HbA1c as a marker of long-term gycemic control.

7.Specimens from patients with polycythemia or post-splenctomy may exhibit increse in HbA1c values due to a somewhat longer life span of the red cells.

DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA
CONSULTANT PATHOLOGIST
MBBS , MD (PATHOLOGY)

440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600
REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)

|			
NAME	: Mrs. GURPREET KAUR		
AGE/ GENDER	: 40 YRS/FEMALE	**PATIENT ID**	: 1563802
COLLECTED BY	:	**REG. NO./LAB NO.**	**: 122407290013**
REFERRED BY	:	**REGISTRATION DATE**	: 29/Jul/2024 11:08 AM
BARCODE NO.	: 12503875	**COLLECTION DATE**	: 29/Jul/2024 11:45AM
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INSTITUTE	**REPORTING DATE**	: 29/Jul/2024 04:37PM
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA		

Test Name	Value	Unit	Biological Reference interval

LIFOTRONIC Graph Report

Name :	Case :	Patient Type :	Test Date : 29/07/2024 15:47:42
Age :	Department :	Sample Type : Whole Blood EDTA	Sample Id : 12503875
Gender :			Total Area : 12406

Peak Name	Retention Time(s)	Absorbance	Area	Result (Area %)
HbA0	70	3013	10490	81.2
HbA1c	38	126	1223	9.5
La1c	25	64	387	3.0
HbF	19	24	22	0.2
Hba1b	13	65	173	1.3
Hba1a	11	37	111	0.9

*** End Of Report ***

DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA
CONSULTANT PATHOLOGIST
MBBS , MD (PATHOLOGY)

440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600
REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)